459836-30-7

Usage

Uses

Used in Pharmaceutical Industry:
NVP-AAM077 is used as an NR2A antagonist for the treatment of neurological disorders. It has been shown to have potential in improving cognitive function and reducing symptoms associated with these conditions.
Used in Research Applications:
NVP-AAM077 is used as a research tool for studying the role of the NMDA receptor subtype NR2A in various neurological processes and disorders. It can help researchers understand the underlying mechanisms of these conditions and develop new therapeutic strategies.
Used in Preclinical Studies:
NVP-AAM077 has been used in preclinical studies as an NR2A antagonist in rats and mice to evaluate its efficacy and safety in treating neurological disorders. These studies provide valuable information on the potential therapeutic benefits and side effects of the drug before it can be tested in clinical trials.

Biochem/physiol Actions

PEAQX is more specific for N-methyl-D-aspartate (NMDA) receptor 2A (NR2A) than N-methyl-D-aspartate (NMDA) receptor 2B (NR2B) and induces striatal apoptosis. It is less potent in activating caspase-3 than its stereomer NVP-AAM007.

Enzyme inhibitor

This potent NMDA receptor antagonist and experimental anticonvulsant (FW = 542.14 g/mol), also known as NVP-AAM077 and tetrasodium [[[(1S)-1-(4-bromophenyl)ethyl]amino](1,2,3,4-tetrahydro-2,3-dioxo-5- quinoxalinyl)methyl] phosphonate, is a competitive antagonist for ionotropic glutamate [N-methyl-D-aspartate] receptors (or GluN receptors). Although originally described as being 100x more active against GluN1/GluN2A receptors versus GluN1/GluN2B receptors, later studies revealed only a 5x difference in affinity. There is no difference in the steady-state levels of inhibition produced by NVP-AAM077 when it was either preapplied or coapplied with glutamate.